Inotiv

Inotiv

Inotiv is a publicly traded contract research organization (NASDAQ: NOTV) headquartered in West Lafayette, Indiana. The company was formed through a series of acquisitions, including the 2021 merger with Envigo and the 2022 acquisition of RSI Group, which built out its research models and services arm. Its wealth origin is not applicable — Inotiv is a corporate entity, not a family office. The firm operates across two main segments: Discovery and Development Services, and Research Models and Services. It covers the full drug development lifecycle from discovery through IND-enabling and pre-marketing authorization. Its service catalogue includes disease pharmacology, toxicology, bioanalysis, genetic toxicology, and cell and gene therapy support. The Research Models segment supplies rodents, rabbits, and nonhuman primates, along with contract breeding, surgical services, and custom antibody production. Inotiv serves clients across North America and Europe. Inotiv reported $120.9M in revenue for the first quarter of fiscal 2026, a 0.8% increase from the prior-year quarter (per SEC filing, February 2026). The company disclosed a cybersecurity incident in February 2026 that affected certain systems (per the firm, February 2026). It does not disclose total professionals count or deployment figures. Adjacent vehicles include the Teklad diet and bedding product line and the Eusoft Labs LIMS platform. Inotiv's structural differentiator lies in its position as a publicly traded CRO that both performs preclinical testing and supplies the animal models used in that testing — an integrated model that few competitors replicate. Its public-company status subjects it to quarterly earnings scrutiny and SEC disclosure requirements, which shapes its capital allocation and operational transparency.